siRNA treatment reduces triglycerides in clients with rare condition

.STUDY HIGHLIGHT.19 September 2024.

Plozasiran minimized triglyceride levels through 80% and also lowered the risk of pancreatitis in clients along with consistent chylomicronemia, with or without a genetic medical diagnosis.